FSD Pharma vs Wheaton Precious Metals Which Should You Buy?

FSD Pharma and Wheaton Precious Metals are two distinct companies operating in different sectors of the market. FSD Pharma is a pharmaceutical company specializing in the development of cannabinoid-based treatments, while Wheaton Precious Metals is a mining company focused on the extraction and sale of precious metals. Both companies have attracted attention from investors due to their potential for growth and profitability in their respective industries. It is important for investors to carefully consider the risks and rewards associated with investing in these stocks before making any decisions.

FSD Pharma or Wheaton Precious Metals?

When comparing FSD Pharma and Wheaton Precious Metals, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between FSD Pharma and Wheaton Precious Metals.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. FSD Pharma has a dividend yield of -%, while Wheaton Precious Metals has a dividend yield of 1.01%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. FSD Pharma reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Wheaton Precious Metals reports a 5-year dividend growth of 10.76% year and a payout ratio of 45.58%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with FSD Pharma P/E ratio at -0.27 and Wheaton Precious Metals's P/E ratio at 45.70. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. FSD Pharma P/B ratio is 0.30 while Wheaton Precious Metals's P/B ratio is 3.84.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, FSD Pharma has seen a 5-year revenue growth of -1.00%, while Wheaton Precious Metals's is 0.25%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with FSD Pharma's ROE at -94.58% and Wheaton Precious Metals's ROE at 8.57%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $0.09 for FSD Pharma and $61.31 for Wheaton Precious Metals. Over the past year, FSD Pharma's prices ranged from $0.09 to $109.19, with a yearly change of 125409.77%. Wheaton Precious Metals's prices fluctuated between $38.57 and $68.64, with a yearly change of 77.96%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.